Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate, ticking off another task for a prospect that could reach regulatory review next year ...
Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics as the Chinese biotech tacks on preclinical neurological assets to its varied portfolio. Shanghai-based OTR raised the ...
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit ...
China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and collaboration deal worth up to ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
LONDON (Reuters) -Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Pfizer-backed biotech landed ...
Investors are weighing Pfizer’s stable dividend and oncology-focused growth strategy against the higher-risk, higher-reward potential of biotech firms. Pfizer is navigating a post-COVID revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results